NeoGenomics spends $125M to expand ops; Cara hires Celgene exec as CMO

→ Cancer-focused genetic test maker NeoGenomics $NEO said it would acquire to acquire Genoptix, an oncology laboratory that specializes in hematology and solid tumor testing for $125 million in cash and 1 million shares of NeoGenomics common stock. With the buy, NeoGenomics is set to expand its coverage of oncology practices and enhance its customer reach.

→ Biopharmaceutical company Cara Therapeutics $CARA, which is developing treatments for itchy skin, has hired Joana Goncalves as chief medical officer, to replace Joseph Stauffer who is transitioning into a consulting role. Goncalves, who most recently served as VP of medical affairs for dermatology and neurology at Celgene $CELG and worked on the biotech’s psoriasis drug Otezla, is tasked with executing the late-stage development of Cara’s Korsuva, an experimental drug for chronic kidney disease-associated pruritus.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->